Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional
Funding Amount
Up to $300,000
Deadline
Forecast — dates not yet posted
Number of Awards
2
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Nonprofits (501(c)(3))
- School districts
- County governments
- Tribal governments
- Nonprofits without 501(c)(3) status
- For-profit businesses
- Public & Indian housing authorities
- Public colleges & universities
Geography
- Regional OrganizationsNon-domestic (non-U.S.) Entities (Foreign Institutions
Other requirements
- Public Housing Authorities/Indian Housing Authorities.
Overview
The objective of this research proposal is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics. The goal of the project is to develop a bottom-up mechanistic PBPK model for these two LAI categories by accounting for the influence of critical formulation attributes of each LAI drug product type to predict its in vivo release mechanism. The model formulation parameters and relevant physiology should be informed with suitable in vitro and in vivo experiments. A suitable preclinical animal model can be used to validate the PBPK model based IVIVCs for both LAI suspensions and polymer based implants. The use of PBPK modelling provides a unique opportunity to understand how the physicochemical properties of drug molecules/polymer, implant specific properties, critical formulation attributes, and physiology, among other things, influence the in vivo release mechanisms of LAI drug products and their disposition characteristics. Moreover, once developed, a mechanistic PBPK model can help to define the 'safe space' for critical formulation attributes relevant to the reference listed drug (RLD) product, explain sources of PK variability and extrapolate predictions to human subjects by leveraging animal model data and by accounting for species-specific physiological differences.
Details
- Agency: Food and Drug Administration
- Department: Department of Health and Human Services
- Opportunity #: FOR-FD-24-002
- Total Funding: $600,000
- Expected Awards: 2
- Instrument: cooperative_agreement
Eligibility
Independent School DistrictsPublic Housing Authorities/Indian Housing AuthoritiesNative American Tribal Organizations (other than Federally recognized tribal governments)Faith-based or Community-based OrganizationsRegional OrganizationsNon-domestic (non-U.S.) Entities (Foreign Institutions
Focus Areas & Funding Uses
Fields of Work
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Minor Use Minor Species Development of Drugs (R01)
Food and Drug Administration
Amount
Up to $250,000
Deadline
January 29, 2027
NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens
Food and Drug Administration
Amount
Up to $200,000
Deadline
April 1, 2027
Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives Clinical Trials Not Allowed
Food and Drug Administration
Amount
Up to $300,000
Deadline
April 1, 2027
Laboratory Flexible Funding Model (LFFM)
Food and Drug Administration
Amount
Up to $1,500,000
Deadline
January 11, 2028
Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
Food and Drug Administration
Amount
Up to $600,000
Deadline
February 8, 2028
Animal and Veterinary Innovation Centers (U18)
Food and Drug Administration
Amount
Up to $1,250,000
Deadline
May 12, 2028
Ready to apply for Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional. Now let's win it.